Oarsman Capital Inc. Purchases 9,483 Shares of Bristol Myers Squibb Company $BMY

by · The Markets Daily

Oarsman Capital Inc. lifted its position in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 36.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 35,640 shares of the biopharmaceutical company’s stock after buying an additional 9,483 shares during the quarter. Oarsman Capital Inc.’s holdings in Bristol Myers Squibb were worth $2,174,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. OMERS ADMINISTRATION Corp grew its position in shares of Bristol Myers Squibb by 0.7% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 112,711 shares of the biopharmaceutical company’s stock worth $6,874,000 after buying an additional 818 shares in the last quarter. D L Carlson Investment Group Inc. bought a new position in shares of Bristol Myers Squibb during the 1st quarter worth $1,510,000. Truvestments Capital LLC grew its position in shares of Bristol Myers Squibb by 779.1% during the 1st quarter. Truvestments Capital LLC now owns 59,796 shares of the biopharmaceutical company’s stock worth $3,647,000 after buying an additional 52,994 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new stake in shares of Bristol Myers Squibb during the 1st quarter worth $147,000. Finally, B. Metzler seel. Sohn & Co. AG lifted its stake in shares of Bristol Myers Squibb by 103.1% during the 1st quarter. B. Metzler seel. Sohn & Co. AG now owns 160,075 shares of the biopharmaceutical company’s stock worth $9,763,000 after purchasing an additional 81,276 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Wall Street Zen cut Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 6th. Citigroup decreased their price target on Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating for the company in a research note on Friday, August 1st. Daiwa Capital Markets cut Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective for the company. in a research note on Tuesday, August 5th. Daiwa America cut Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. Finally, Morgan Stanley restated a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $56.38.

Read Our Latest Stock Report on Bristol Myers Squibb

Bristol Myers Squibb Stock Up 0.8%

Shares of BMY opened at $47.60 on Thursday. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb Company has a 12 month low of $42.96 and a 12 month high of $63.33. The stock’s 50 day moving average is $47.04 and its two-hundred day moving average is $50.90. The firm has a market cap of $96.88 billion, a P/E ratio of 19.19, a PEG ratio of 2.41 and a beta of 0.36.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The company had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. During the same period last year, the company earned $2.07 earnings per share. Bristol Myers Squibb’s quarterly revenue was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were given a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 5.2%. The ex-dividend date was Thursday, July 3rd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 100.00%.

Bristol Myers Squibb Profile

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Featured Articles

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).